In fact, the European Commission itself stipulated that the rest of the UK could continue acting as a “hub” for generic medicines for Northern Ireland.
It added that “this proposal involves the EU changing its own rules on medicines”, as it would allow what is technically still part of the single market to be regulated by a non-EU country.
However, there are worries that if negotiations were to end without agreement, the EU could impose its own regulatory requirements on medicines entering Northern Ireland.
Medicines distributors have previously said that triggering Article 16 would maintain the status quo in the short term, but would have long-term implications to medicines access in the whole of the UK.
postbrexitcompliance.com 